CreditRiskMonitor is a financial risk analysis and news service for credit, supply chain and financial professionals.  Our strength in coverage spans 58,000 global public companies, totaling about $70 trillion in corporate revenue.  We also offer solutions that can help ease private company financial risk assessment.  Leading corporations around the world – including more than 35% of the Fortune 1000, plus thousands more worldwide – rely on us to help them stay ahead of financial risk quickly, accurately and cost-effectively. 

A partial report preview for Zhejiang CONBA Pharmaceutical Co., Ltd. is shown below.  Where indicated by "Yes," CreditRiskMonitor contains this information in its extensive database.  To get access to the full report and learn more about CreditRiskMonitor's robust financial risk analysis and timely news service, request a personalized demo and free trial today.

If you are already a subscriber and want to access the full report, click here.

Zhejiang CONBA Pharmaceutical Co., Ltd.
No. 568, Binkang Road, Binjiang District
Phone: +86 57187774288p:+86 57187774288 HANGZHOU, ZHJ  310052  China Ticker: 600572600572
Business Summary
Zhejiang CONBA Pharmaceutical Co Ltd is a China-based company mainly engaged in the research, development, manufacturing and sales of pharmaceuticals, traditional Chinese medicine decoction pieces and health products. The Chinese medicine products includes prepared Chinese medicines, raw Chinese medicinal materials and processed Chinese medicinal herbs, Chinese medicine health products, and Chinese medicine extracts. The main products include the CONBA Changyanning series, the Jin Di compound houttuynia mixture series, the Qianliekang Prolean series, the Tianbaoning Ginkgo biloba series and Zhixinli musk heart-clearing pills, as well as Chinese medicinal herbs such as Astragalus membranaceus and Codonopsis pilosula. The Company also manufactures and sells specialty chemical preparations, raw materials, and nutritional supplements. The drugs are mainly used to treat cardiovascular, digestive, respiratory and urinary system diseases, as well as for anti-infection purposes.

Scores and Ratings
FRISK®
Score		 Z''
Score		 PAYCE®
Score		 DBT
Index		 Moody's
Rating		 Fitch
Rating		 DBRS
Rating
YesYes-----

Financials, News and Filings
Latest
Statement		 Last
Audit
News		 SEC
Filings		 Bankruptcy
Filings		 Suit &
Judgment
Filings		 Tax
Lien
Filings
9/30/202512/31/2024Yes----

Industries
SIC Code Description
2833 Medicinal chemicals and botanical products
2834 Pharmaceutical preparations
2099 Food preparations, not elsewhere classified
2836 Biological products, except diagnostic substances
5099 Durable goods, not elsewhere classified
3842 Orthopedic, prosthetic, and surgical appliances and supplies

Officers and Directors

Title
Name
Age		 Title
Date		 Start
Date
Executive Chairman of the Board XujieYing 52 12/30/2025 12/22/2025
President, Director FanZhou 47 5/23/2025 4/2/2025
Vice Chairman of the Board JunliJin 45 12/30/2025 12/22/2025
10 additional Officers and Directors records available in full report.

Business Names
Business Name
600572
Zhejiang Conba Pharmaceutical Co., Ltd.

General Information
Number of Employees: 8,258 (As of 12/31/2024)
Outstanding Shares: 2,536,675,041 (As of 3/9/2026)
Shareholders: 95,479
Stock Exchange: SHA
Fax Number: +86 57187774722


Copyright © 2026 CreditRiskMonitor.com (Ticker: CRMZ). All rights reserved.     
By using this website, you accept the Terms of Use Agreement.
Tuesday, March 24, 2026